• Publications
  • Influence
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRCExpand
  • 1,217
  • 68
  • PDF
Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
F. A. Peccatori1, H. A. Azim Jr2, R. Orecchia3, H. J. Hoekstra4, N. Pavlidis5, V. Kesic6 & G. Pentheroudakis5, on behalf of the ESMO Guidelines Working Group* Fertility and Procreation Unit, DivisionExpand
  • 416
  • 26
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up F. Pacini, M. G. Castagna, L. Brilli & G. Pentheroudakis On behalf of the ESMO Guidelines Working Group*Expand
  • 261
  • 20
Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
A. Berruti1, E. Baudin2, H. Gelderblom3, H. R. Haak4, F. Porpiglia5, M. Fassnacht6 & G. Pentheroudakis7 on behalf of the ESMO Guidelines Working Group* Medical Oncology, Department of Clinical andExpand
  • 248
  • 14
Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
K. Fizazi1, F. A. Greco2, N. Pavlidis3, G. Daugaard4, K. Oien5 & G. Pentheroudakis3, on behalf of the ESMO Guidelines Committee* Department of Cancer Medicine, Institut Gustave Roussy, University ofExpand
  • 106
  • 13
  • PDF
Switching benchmarks in cancer of unknown primary: from autopsy to microarray.
INTRODUCTION Cancer of unknown primary (CUP) is associated with unknown biology and dismal prognosis. Information on the primary site of origin is scant and has never been analysed. We systematicallyExpand
  • 195
  • 12
Cancer and pregnancy: poena magna, not anymore.
Cancer diagnosed during pregnancy constitutes a difficult clinical condition with a devastating impact on the patient's somatic and psychosocial health and possibly on foetal integrity. ThisExpand
  • 219
  • 11
Cancer of unknown primary site
Cancer of unknown primary site (CUP) is a well recognised clinical disorder, accounting for 3-5% of all malignant epithelial tumours. CUP is clinically characterised as an aggressive disease withExpand
  • 187
  • 9
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
R. Dummer1, A. Hauschild2, N. Lindenblatt3, G. Pentheroudakis4 & U. Keilholz5, on behalf of the ESMO Guidelines Committee* Department of Dermatology, University Hospital Zürich, Zürich, Switzerland;Expand
  • 240
  • 9
  • PDF
Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature.
INTRODUCTION Although more than 90% of melanomas have a cutaneous origin, occasionally it is discovered as a secondary deposit without evident primary site. The aim of this study was toExpand
  • 95
  • 8